COVID 19: A Case Series of Diverse Clinical Presentations at a Tertiary Hospital in Nigeria

Adegoke Oluwakemi T^1, , Bamigboye-Taiwo Olukemi T¹, Afeniforo Olufunke G¹, Okeniyi John A¹, Omotoye Babatunde S², Olorunmoteni Oluwatosin E¹ and Adegoke Adedokun I³

¹Department of Paediatrics, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria

²Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria

³Department of Obstetrics and Gynaecology, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria

Cite this paper

Adegoke Oluwakemi T, Bamigboye-Taiwo Olukemi T, Afeniforo Olufunke G, Okeniyi John A, Omotoye Babatunde S, Olorunmoteni Oluwatosin E and Adegoke Adedokun I. COVID 19: A Case Series of Diverse Clinical Presentations at a Tertiary Hospital in Nigeria. American Journal of Medical Case Reports. 2022; 10(2):29-34. doi: 10.12691/AJMCR-10-2-3

Abstract

COVID-19 is a disease which originated in China in 2019 and has rapidly spread to become a pandemic. COVID-19 is less common in children and young adults and cases among this group of individuals are usually not as severe as in the elderly, the immunocompromised or those with co-morbidities. Research of COVID-19 in children is not as robust as in adults probably due to the aforementioned reason. We report four cases of COVID-19 in children who had mild to severe disease course. These children had other co-morbid illnesses such as malaria, bacterial sepsis and rheumatic heart disease. Two of these children had rarer severe complications of the disease hardly reported in children, these were; pleural effusion and cholestatic liver disease. It may be important to screen every child that requires hospital admission for COVID-19 in order to make early diagnosis of the disease and to commence appropriate therapy where necessary. This may forestall development of complications including death in such children.

Keywords

COVID-19, sepsis, cholestatic jaundice, malaria, pleural effusion, rheumatic heart disease

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID 19. Nat Rev Microbiol, 19: 141-154, 2021.
[2]	World Health Organization. Rolling updates on coronavirus disease (COVID-19). Updated 31 July 2020. Available from https: www.who.int/emergencies/diseases/novel-coroa-2019/events-as-they-happen. [Accessed June 2, 2021].
[3]	Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care, 24:422 2020.
[4]	Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child, 106:429-439, 2021.
[5]	Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis, e276-e288, Nov. 2020. [Accessed June 4, 2021].
[6]	Beaton A, Zühlke L, Mwangi J, Taubert KA. Rheumatic heart disease and COVID-19. Eur Heart J, 41(42): 4085-4086, Nov 2020.
[7]	Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf M-I, Benstoem C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.:CD015043. [Accessed August 10 2021].
[8]	Butler-Laporte G, Nakanishi T, Mooser V, Morrison DR, Abdallah T, Adeyeye O, et al. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. PLoS Med 18(6): e1003605. [Accessed Aug. 12, 2021].
[9]	Eid MM. Co-infection with COVID-19 and malaria in a young man. Dubai Med J, 4:164-166, 2021.
[10]	Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect, 26(12): 1622-1629, Dec 2020.
[11]	Westblade LF, Simon MS, Satlin MJ. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol, 29(10): 930-941, Oct 2021.
[12]	He S, Liu W, Jiang M, Huang P, Xiang Z, Deng D, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study. PLoS ONE, 16(4): e0249668, April 2021. [Accessed Aug. 20, 2021].
[13]	Merola E, Pravadelli C, de Pretis G. Prevalence of liver injury in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Acta Gastroenterol Belg, 83(3):454-460, July-Sept 2020.
[14]	Yu D, Du Q, Yan S, Guo X, He Y, Zhu G, et al. Liver injury in COVID-19: clinical features and treatment management. Virol J, 18: 121, 2021.
[15]	Da BL, Suchman K, Roth N, Rizvi A, Vincent M, Trindade AJ, et al. Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality. J Int Med, 290(2): 470-472, Aug, 2021.
[16]	Fu L, Fei J, Xu S, Xiang H, Xiang Y, Hu B, et al. Liver dysfunction and its association with the risk of death in COVID-19 patients: a prospective cohort study. J Clin Transl Hepatol, 8(3): 246-254, Sep. 2020.
[17]	Chong WH, Saha BK, Conuel E, Chopra A. The incidence of pleural effusion in COVID-19 pneumonia: State-of- the-art review. Heart & Lung, 50(4):481-490, 2021.
[18]	Rathore SS, Hussain N, Manju AH, Wen Q, Tousif S, Avendano-Capriles CA, et al. Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systemic review and meta-analysis. J Med Virol, 1-11, 2021.